Everotas 5mg tablet - Everolimus | Myapplepharma

DESCRIPTION

Everotas 5mg belongs to a class of anti-cancer drugs. Everotas 5mg contains an active compound known as Everolimus which interferes with the development of cancer cell and the process is slowed down. Everotas 5mg tablets is not a curable medication, which helps to slow their spreading into the body.

PRESCRIBED FOR

The drug Everotas 5mg is mainly used for the treatment of the following disease
kidney carcinoma
Breast carcinoma
Brain carcinoma
Everotas 5mg is also used to treat in various advanced stage cancer in stomach, intestines or pancreas.

CLINICAL PHARMACOLOGY OF EVEROTAS

Everolimus is a prohibition of mTOR, links at peak compatibility to FK506 binding protein 12, through producing drug complex which prevents the productive of mTOR. This inhibition reduces the activity of effectors downstream, which may lead to stoppage of cell progression from G1 into S phase, finally causes cell growth arrest and apoptosis. Everotas also prohibits the expression of hypoxia-inducible factor, causing to a reduces in the expression of vascular endothelial growth factor. The result of everolimus prevention of mTOR is a reduction in cell multiplication, angiogenesis, and glucose uptake.

DOSAGE

Everotas 5mg tablets should be given with or without food. The dosage regimen of Everotas; In breast cancer, renal cell cancer, pancreatic cancer, Neuroendocrine cancer: The prescribed dosage is 10mg should be taken as a single dose. In Brain or intracranial cancer: The prescribed dosage of Everotas as a single dose. is 4.5mg/m2 given orally In pediatric: The pediatric dosage of Everotas as a single dose in the brain or intracranial tumor is 4.5mg/m2 should be given orally.

SIDE EFFECTS

Nephrotoxicity
Thrombocytopenia
Hypersensitivity reactions
Hyperlipemia
Angioedema
Lymphomas & other malignancy
Male infertility
Proteinuria

DRUG-DRUG INTERACTION

Interaction of Everotas 5mg with a strong inhibitor of CYP3A4, or P-gp, cause reducing the efflux of Everolimus and high plasma concentration of Everolimus. Concomitant use of Everotas 5mg with strong CYP3A4 inducers will increase the disclosure of Everolimus. Interaction of Everotas 5mg with cyclosporine will be increasing the AUC level of Everolimus frequently.

PREGNANCY

Pregnancy category of Everolimus C: In patients, Everotas 5mg is used only after knowing the benefits to the mother exceed the risk to the fetus.

LACTATION

Breastfeeding should not be suggested

STORAGE

Everotas 5mg tablet store at 25° Protect the medicine away from moisture, heat, and light.

MISSED DOSE

If the patients missed the dose, patients must consult with the medical practitioner and follow the instructions given by them. Or missed dose should be avoided and follow the regular dosing schedule.


FOR MORE INFORMATION

EMAIL:


applepharmaceutical@gmail.com

PHONE:


91- 9987711567

Comments

Popular posts from this blog

Cabozantinib (Cometriq, Cabometyx) tablet Online | Apple pharmaceuticals

Evertor 10mg tablet - Everolimus | Myapplepharma